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Abstract
Purpose of review—Eosinophilic gastrointestinal diseases (EGIDs) are an increasingly
common heterogeneous group of intestinal diseases. The purpose of this review is to present the
latest developments in the care of patients with EGIDs and to summarize a growing literature
defining the clinical features and mechanistic elements of eosinophils and their complex
relationships with the gastrointestinal tract.
Recent findings—Recent studies continue to define what constitutes ‘normal’ and ‘abnormal’
numbers of eosinophils in the different sections of the gastrointestinal tract. Symptom complexes
of EGIDs appear to be related primarily to the mucosal, as opposed to the muscular or serosal,
forms of EGIDs. Dissection of the mucosal microenvironment is uncovering a complex array of
cells, other than eosinophils, that likely contribute to the inflammatory response associated with
EGIDs. Mechanistic studies have identified genetic perturbations (eotaxin-3, thymic stromal
lymphopoietin, IL-13, and filaggrin) that may also contribute to the development of the most often
encountered and well studied EGID, eosinophilic esophagitis.
Summary—Clinicians should remain aware of EGIDs as a diagnostic possibility for patients
with common gastrointestinal symptoms. Additional research is needed to determine mechanistic
processes leading to dysfunction associated with eosinophilic gastrointestinal inflammation.
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Introduction
Over the last decade, eosinophilic gastrointestinal diseases (EGIDs) have become
increasingly recognized as a clinically relevant and mechanistically baffling group of
conditions. Inherent in the diagnosis of these diseases is the finding of ‘more than expected’
eosinophils in the gastrointestinal tissues; what defines this number is an area of controversy
and intrigue. Herein, we summarize clinical studies and identify controversies related to
EGIDs.
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Gastrointestinal eosinophilia: what is in a number?
Except for the esophagus, all of the remaining gastrointestinal organs contain eosinophils.
But, the ambiguity of what constitutes normal and abnormal numbers of eosinophils,
contributes to significant confusion revolving around the care of patients with, and
pathophysiological mechanisms defining, EGIDs. What are the diagnostic features of these
diseases? What are the underlying homing and activation signals that drive the associated
eosinophilic inflammation and the gastric, intestinal and/or bowel dysfunction in patients
with EGIDs?
To date, the number of eosinophils per high power field (HPF) in a mucosal biopsy remains
the gold standard defining histological diagnostic features of EGIDs [1]. Methodologies
used to define these thresholds remain troublesome for several reasons including
inconsistencies in definitions of what constitutes an eosinophil and the size of a HPF,
variability in analysis between pathologists and gastrointestinal/allergy clinicians [2],
inconsistencies in tissue orientation, limited amount of mucosal surface to assess, and most
confusing, what defines normal and abnormal eosinophil numbers within various parts of the
intestinal mucosae. Pathologists remain central to the diagnostic process [3–7].
If one considers EGIDs as a diagnosis, it is worth communicating with the pathologists to
understand exactly how and why the specific inflammatory features are reported so that the
results can be interpreted in the clinical context from which they were obtained. As these
diseases become more common, patients and families are more informed and are beginning
to understand how difficult these critical parameters are to define and, thus, may request
more information about pathological reports.
Relatively few studies characterize what defines the normal number of eosinophils in the
healthy gastrointestinal mucosae. This is a particularly difficult area of investigation because
endoscopic sampling of the mucosa would not take place unless a clinical indication existed.
One study began to address this issue by counting eosinophils in ‘whole tissue sections’
from the intestines of otherwise healthy infants and children who died acutely of causes
other than gastrointestinal disease (trauma, etc.) [8]. Children ranged in age from 3 weeks to
17 years and a gradient of eosinophil numbers was identified ranging from a few in the
stomach to a maximum of 50/HPF in the cecum. Another pediatric study showed virtually
the same findings in ‘mucosal biopsy samples’ [9]. A third study examined histological
features of the intestinal ‘mucosal biopsy samples’ from patients who exhibited a wide range
of clinical features and found a similar gradient in the upper gastrointestinal tract [10]. Other
studies determined the ‘normal’ number of eosinophils in the gastric mucosa (15 eos/HPF),
colon (approximately Eosinophilic gastrointestinal diseases: clinical features of a
heterogeneous group of conditions
Although a number of case reports have described the association of gastrointestinal
symptoms with intestinal eosinophilia, the first and earliest comprehensive descriptions were
provided by Kaijser [15] and Klein et al. [16] in publications separated by 33 years. In 1937,
the single authored German publication by the surgeon Kaijser [15] described a series of
patients with various abdominal symptoms and intestinal eosinophilia. In 1970, Klein et al.
[16] proposed a novel classification system that separated patients with intestinal
eosinophilia into anatomically distinct groupings, that is, mucosal, muscular, or serosal
diseases, depending on where the predominant eosinophilia was located.
Subsequent to this, a number of investigators have further refined the description of EGIDs
as organ-specific diseases, that is, eosinophilic esophagitis (EoE), eosinophilic gastritis,
eosinophilic gastroenteritis, and eosinophilic colitis, depending on which part of the
gastrointestinal tract is affected by eosinophilic inflammation [17]. Because eosinophils can
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infiltrate the mucosa as a nonspecific feature of inflammation, other causes of eosinophilia
need to be ruled out prior to assigning EGID as a diagnosis [18] (Table 1).
EoE is characterized by symptoms related to esophageal dysfunction; in the young child,
symptoms include vomiting, abdominal pain, and feeding problems, whereas in older
children and adults, dysphagia and food impactions [19] predominate [20,21]. Symptoms
attributed to gastroesophageal reflux disease (GERD) that are recalcitrant to medical/
surgical management of GERD can be, but are not always, presenting features of EoE [22].
Epidemiological data report an overall incidence of EoE as 1–5 in 10 000 with male sex
predominance. Case series are increasing from previously underreported regions such as
some parts of Europe, the Middle East, and Asia [4,23–25]. A family history of esophageal
dilations is common. As the incidence grows and phenotypic descriptions expand,
histological patterns are becoming more important. Eosinophil numbers remain the
histological diagnostic feature but other components such as extracellular eosinophil granule
deposition and other measures of inflammation (basal cell hyperplasia, rete peg elongation,
dilated intercellular spaces, mastophilia, T cells, fibrosis, etc.) are also increased in the
esophageal mucosa [26,27–30,31,32]. With respect to granule deposition, several studies
have addressed this issue and suggest that the presence of extracellular granules occurs more
often in the mucosa affected by EoE compared to GERD [33–36] (Fig. 1). A recently
updated consensus report summarizes the most recent experiences and literature focusing on
the clinical features and treatment of EoE [21]. See Table 2 for a summary of the changes
from the original report [20].
Eosinophilic gastritis can present with abdominal pain, hematemesis, or vomiting alone,
whereas eosinophilic gastroenteritis can manifest itself with these symptoms as well as
anemia, diarrhea, or protein-losing enteropathy. Eosinophilic colitis typically can present
with similar symptoms as above as well as bloody stools and can be mistaken for
inflammatory bowel diseases. Two studies arising from tertiary care centers reported the
world’s largest clinical experiences and descriptions of the natural history of adults with
EGIDs [37,38]. Talley et al., according to the Klein classification system, reported that over
the course of the past 50 years, the pattern of EGIDs involvement has shifted to primarily a
mucosal form. They note that 3 of the 4 million patients from their extensive database were
found to have EGIDs and the incidence increased from one patient per year from 1950 to
1987 to three patients per year between 1987 and 2007. Follow-up revealed no significant
complications.
Treatments for EGIDs remain limited to corticosteroids and diet restriction. EoE can
effectively be treated with topical steroids [39,40], nutritional exclusions, and dilation [41–
44]. Clinical experiences suggest that the more distal the eosinophilia from the esophagus,
the less likely that a dietary allergen will be found to resolve symptoms and
histopathological findings. In some circumstances, mast cell stabilizers and leukotriene
antagonists may offer clinical benefit but no clinical trials have been performed. Novel
biological agents such as anti-IL-5 antibody are on the horizon as potential new therapeutic
agents for EoE and potentially other EGIDs.
Pathogenetic mechanisms: do not assume the obvious - could eosinophils have a
homeostatic role in the gastrointestinal tract of healthy individuals?
The overwhelming focus of investigations linking pathology and symptoms in EGIDs often
views the eosinophil as an interloper, a marauding proinflammatory leukocyte whose
recruitment is a prelude to tissue destruction. However, this portrayal of the eosinophil
belies the reality that, with the exception of the esophagus, the eosinophil is a prominent
resident leukocyte of the gastrointestinal tract as discussed above and by others [45,46]. The
presence of these resident eosinophils in otherwise healthy individuals leads to a paradox:
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how is the presence of eosinophils necessary to maintain homeostasis at baseline and yet
their presence is a hallmark and defining feature of EGIDs? We suggest that a better
understanding of this paradox and, in turn, its resolution will provide a unique perspective to
understand the role of eosinophils in EGIDs. There are three potential explanations for this
paradox. First, resident eosinophils serve no role in the gastrointestinal tract in healthy
individuals. As surprising as this statement may be, it had been one of the more common
explanations offered for the presence of gastrointestinal eosinophils. In this hypothesis, the
toxic character of eosinophils necessitated an extraordinary mechanism to remove these cells
from the body. The gastrointestinal tract offered such a mechanism by acting as a sink for
peripheral eosinophils as a means to remove these cells without collateral damage. Second,
the activities of resident gastrointestinal eosinophils are inherently different from the
pathological activities mediated by the recruited eosinophils accumulating as part of disease.
Clearly, if one assumes that resident eosinophils have a functional role in healthy individuals
and a pathological role in disease, the most parsimonious explanation for this duality is that
the activities mediated by these two eosinophil populations are different. Indeed, the
literature abounds with suggestions that eosinophils undergo one or more events leading to
an inflammatory leukocyte that is unique relative to the ‘resting’ eosinophils found in
peripheral circulation. These suggestions took many forms. On a morphological level, it was
suggested that inflammatory eosinophils were hypodense relative to their ‘resting’
counterparts [47,48]. However, this vague more qualitative characterization gave way to
specific molecular markers that correlated with the events described as eosinophil ‘priming’
or ‘activation’ [49–51]. As it related to the gastrointestinal tract, resting eosinophils may be
sentinels whose presence was an early defensive shield to the possibility of microbial
infection in a region that represented the largest environmental interface the body offers
[52,53]. Thus, low numbers of eosinophils serve as sentinels that activate and multiply in
number when confronting an infection. That is, gastrointestinal eosinophils in healthy
individuals were ‘resting’ leukocytes that were triggered in response to pathogen. In this
paradigm, EGIDs represent a form of immune dysfunction mimicking the events linked with
parasite infection and in doing so, inadvertently unleash the nonspecific destructive
capabilities of eosinophils; the ensuing tissue damage and local inflammatory events simply
being unavoidable collateral damage. The third explanation for the presence of eosinophils
in both health and disease suggests that resident eosinophils and those recruited during
disease have exactly the same functions. The key for this hypothesis is that changing events
in the gastrointestinal microenvironment elicit increases in the number, but not the activities,
of eosinophils. The dynamic changes occurring in disease simply require more of the same
eosinophil-mediated activities to maintain homeostasis. The fundamental issue in the case of
the gastrointestinal tract is how eosinophils contribute to gut homeostasis and why are
greater numbers of them required in disease states. Specifically, are these cells part of the
immunomodulation of the mucosal microenvironment or are they agents of remodeling/
repair linked to the continual and dynamic turnover of the gut epithelium? The point of
interest here is that these proposed eosinophil activities are qualitatively the same in health
and disease [54]. In this perspective, the immunoregulatory demands on the gut mucosal
interface are enormous given the ubiquitous bacterial burden in this compartment. As such,
the loss of epithelial barrier functions associated with many gastrointestinal diseases
becomes a driver of eosinophil accumulation in these patients. Finally, epithelial cell
turnover and stem cell activities require an ongoing commitment to remodeling/repair even
in otherwise healthy individuals. Again, the damage linked with disease pathology would
simply necessitate an increase in eosinophil numbers and, in turn, eosinophil-mediated
remodeling/repair activities.
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Eosinophilic esophagitis: increasing evidence for Th2 responses
Clinical practice is shedding light on the identification of different subtypes of patients with
EoE, whereas translational and basic studies continue to provide more insights into the key
elements defining the pathogenesis of this disease [55]. Together, these experiences and
studies will provide direction toward novel therapeutic targets.
Genes
In addition to eotaxin-3, a number of other genes have now been associated with EoE,
including transforming growth factor (TGF)-[beta]-1, filaggrin, and thymic stromal
lymphopoietin (TSLP) [56–59]. TSLP is an epithelial derived IL-7-like cytokine that can
activate a number of immune cells, in particular dendritic and mast cells. Filaggrin is a
barrier gene that has been linked to barrier dysfunction in atopic dermatitis.
Epithelial immunomilieu: a diverse microenvironment is under definition
Eosinophils are the most readily recognized leukocyte associated with EoE, but they are not
the only cells present in the affected esophageal mucosal surface. Studies measuring FoxP3
staining and human leukocyte antigen-DR expression in children and adult mucosae have
been met with variable results [60–62]. A cell line of esophageal epithelia has been shown to
possess the machinery to present antigen posing an interesting new paradigm for the
pathogenesis of EoE [63].
Esophageal mucosae of adults and children with EoE were shown to have significantly
increased mast cells [26,31,64]. Fibroblast growth factor expression in EoE tissues from
children was associated with peripheral blood mononuclear cell expression of pro-apoptotic
factors Fas and caspase-8 suggesting prolongation of eosinophil lifespan [65]. Although
these studies continue to define the microenvironment associated with EoE, all patients may
not have the same immunomilieu; future studies identifying the exact immunological
features of specific clinical phenotypes may be difficult to measure but will be important to
determine.
Mouse models and ex-vivo systems using human tissues support the concept that EoE is a
Th2-driven disease. A recent comparative analysis of five EoE patients with five normal
patients revealed more than four-fold upregulation of 19 cytokine genes (including
eotaxin-3, IL-13, IL-5, IL-5r, CXCL1) and downregulation of two genes [breast and kidney-
expressed chemokine (BRAK) and IL-1F6] [66]. Of the upregulated genes, there was a
significant correlation with disease activity. Other studies suggest EoE may be an IL-13 and/
or IL-15 epithelial driven disease [67,68]. For instance, IL-15r null mice were protected
from eosinophilia [67]. Ex-vivo analysis of esophageal epithelia revealed expression of both
IL-15 and IL-15r, a finding that correlated with mucosal eosinophilia.
Chronic inflammation: mechanistic insights and functional impaction
The major clinical concern regarding chronic esophageal eosinophilia has been the impact of
eosinophils and their products on remodeling, fibrosis, and stricture formation. This later
potential impact has driven much of the vigor and attention to treatments. Clinical correlates
identify increased fibrosis in the esophageal mucosa of children and adults with EoE, but
criteria to measure this feature remain variable. To address this concern, a series of works
identified a prominent role for TGF-[beta] in remodeling events in EoE and demonstrate a
role for mast cells and TGF-[beta] in esophageal smooth muscle contraction [26].
Methodologies to measure esophageal function are lacking.
Recently, a study using the novel tool the endoflip, demonstrated reduced esophageal
compliance in adults with EoE, a finding supportive of fibrosis or possibly increased
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esophageal tone [69]. Together, these findings support the concept that eosinophilia can
contribute to esophageal dysmotility, but who, how, and when these issues develop is
unknown.
Eosinophilic gastritis and colitis: mechanistic elements
Although studies of the esophagus and other organ systems such as the lung have identified
potential roles for eosinophils in stimulating tissue remodeling, inducing epithelial barrier
dysfunction and smooth muscle contraction, few studies have addressed these issues in the
rest of the gastrointestinal tract.
Previous studies focusing on the mechanisms of eosinophil recruitment identified the role of
eotaxin-1 in the chemotaxis of eosinophils to the gastrointestinal mucosa. Utilizing bone
marrow chimeras, a recent study demonstrated the impact of Ly6ChighCCR2+ monocyte/
macrophage CCL11 on eosinophil recruitment in dextran sodium sulfate colitis [70]. A few
studies have examined the impact of eosinophils on colonic function utilizing models of
inflammatory bowel diseases.
For example, oxazolone-treated mice develop a Th2-type cytokine and colonic eosinophilia
profile similar to ulcerative colitis [71]. Use of this mouse model in eosinophil granule
protein null animals has demonstrated the pathological impact of major basic protein (MBP)
and eosinophil peroxidase (EPO) in colitis.
Two studies showed that mice congenitally deficient in eosinophil development are
protected from experimental colitis [71,72]. A spontaneous mouse model of ileitis, the
SAMP1 mice, develops eosinophilia and ileal remodeling [73]. Mice treated with anti-CCR3
antibody responded with diminished eosinophilia, decreased goblet cell hyperplasia, and
decreased smooth muscle mass [74].
Together, these studies support a role for eosinophils in lower gastrointestinal remodeling
and dysfunction
Because of the potential role of allergic T-cell responses, IgE-mediated reactions have been
considered as one of the mechanisms contributing to EGIDs. As such, anti-IgE therapy was
used to treat eight patients with EGIDs. A 16-week trial of omalizumab resulted in no
impact on T-cell proliferation, antigen dose responses, precursor frequency, or cytokine
expression [75]. These findings do not support a direct role for IgE in EGIDs.
Eosinophils express a number of cytokine receptors, including those associated with
remodeling and fibrosis: IL-13, TGF-[beta], and tumor necrosis factor (TNF). Eosinophils
can respond differently to their microenvironment, inducing expression of either Th1 or
Th2-associated chemokines and, thus, may play a role in orchestration of the immune milieu
in EGIDs.
Numerous histological studies have described increased eosinophil presence in intestinal
mucosal biopsies. In addition, granule proteins have been detected in colonic perfusion
fluids and stool samples from patients with intestinal inflammation. Thus, eosinophils are
present and secrete their granule contents.
However, the role and function of the eosinophil in intestinal inflammation remains unclear.
Eosinophils while containing an armamentarium of molecules shown to elicit dysfunctional
effects in other organs, particularly the lung, have not yet been examined in detail in the
intestines. In this regard, immunohistochemical assessment of human tissues affected by
inflammatory bowel diseases demonstrates increased staining for EPX suggesting a potential
role for eosinophil activation in these diseases (Fig. 2). Further basic and translational
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investigations are necessary in this area to provide insights into eosinophil response to tissue
microenvironments, mechanisms contributing to pathology and descriptions of patient/
disease phenotypes, and may lead to novel targeted therapeutic options for these EGIDs.
Conclusion
In summary, eosinophils continue to be enigmatic cells that likely serve a role in health and
disease. Eosinophil enumeration continues to be the gold standard for fulfilling the
histological diagnostic parameter, but future studies will characterize other meaningful
criteria that may not only include histology, but also molecular parameters. Functional
studies of EGIDs are lacking and much needed to understand the physiological and
pathophysiological roles of eosinophils in the gastrointestinal tract. Because of the overall
rarity and mechanistic overlaps of EGIDs, collaborative, multidisciplinary studies will
provide the most rapid and meaningful discoveries.
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Key Points
• The normal number of eosinophils in the stomach, small intestine, and colon
continues to undergo definition and may be influenced by a number of different
factors
• Eosinophilic inflammation of the gastrointestinal tract is a nonspecific finding.
• Eosinophilic gastrointestinal diseases (EGIDs) are characterized by common
gastrointestinal symptoms and eosinophil predominant inflammation. Other
causes for symptoms and inflammation should be ruled out before assigning a
diagnosis of EGIDs.
• Basic studies identify pathogenetic roles for eosinophils in murine models of
colitis and intestinal remodeling.
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Figure 1. Eosinophils in eosinophilic esophagitis
Hematoxylin and eosin and eosinophil peroxidase staining of the esophageal tissue from a
patient with eosinophilic esophagitis (EoE). EPX antibody (Clone: MM25-82-2) was used to
stain a section from a patient with EoE. EPX (black dots) staining is evident in the squamous
epithelia that is not easily evident in the hematoxylin and eosin stained tissue.
Masterson et al. Page 13
Curr Opin Gastroenterol. Author manuscript; available in PMC 2014 February 06.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Eosinophil peroxidase staining of ileal tissue from patients with Crohn’s disease
EPX antibody (Clone: MM25-82.2) was used to stain mucosal biopsy and resection tissue
from children with (a) no evidence of inflammatory disease (b) Chron’s disease untreated,
and (c) Chrons’s disease following steroid treatment. EPX (black dots) staining is evident in
the lamina propria. Reduced eosinophil numbers were observed following treatment.
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Table 1
Differential diagnoses for intestinal eosinophilia
Esophageal Small intestinal and colonic
Gastroesophageal reflux disease Food hypersensitivity
Eosinophilic esophagitis Eosinophilic gastrointestinal disease
Eosinophilic gastroenteritis Crohn’s disease
Celiac Ulcerative colitis
Crohn’s disease Celiac disease
Achalasia Churg-Strauss Syndrome
Connective tissue disease Systemic lupus erythematosus
Hypereosinophilic syndrome Infections: Ancylostoma duodenale, Anisakiasis, Basidiobolomycosis,
Enterbious vermicularis, Helicobacter pylori, Schistomiasis,
Toxacara canis
Infectious: Candida, Herpes virus Malignancy
Drug hypersensitivity response
Vasculitis
Pemphigoid vegetans
Graft-versus-host disease
Other causes of Chronic vomiting (Amoid–Chiari malformations,
gastric dysmotility, etc.)
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Table 2
2 Changes to original eosinophilic esophagitis consensus recommendations
Abbreviation change from ‘EE’ to ‘EoE’ The acronym EE is confused with erosive esophagitis, thus the change to EoE
Use of word ‘chronic’ Increasing experience and studies identity EoE as a chronic disease requiring long-term follow-up
and management
Use of terms ‘immune/antigen-driven’ Clinical, translational, and basic studies identify potential aberrant immune response as
pathogenetic features of EoE
Some patients with EoE may present
with less than 15 eosinophils/HPF
A small numbers of patients with EoE might have less than the threshold number of eosinophils,
Potential reasons for this include inadequate biopsy specimen number, sampling error,
longstanding chronic disease that resulted in remodeled tissue, or partial treatment response to use
of other topical steroids for concomitant nasal or respiratory allergies
Introduction of term ‘pump inhibitor
(PPI)-responsive esophageal
eosinophilia’
PPIs may have anti-inflammatory or barrier-healing properties that contribute to resolution of
esophageal eosinophilia
EoE. eosinophilic esophagitis; HPF, high power field. Modified from [21•].
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